In the News
GSK hit by fine for anti-competitive behaviour
Graham Watson
12th February 2016
Quelle surprise - on being fined for anti-competitive behaviour, GSK deny the allegations and argue that they brought the drugs of their generic rivals to the market earlier, saving the NHS money. Quite why a profit-maximising firm would act in this fashion, I don't know but I'm smelling a rat not least because "the CMA pointed out that after generic paroxetine entered the market properly at the end of 2013, average prices for the drug fell more than 70% in two years. More here from the CMA website.
You might also like
Barriers to Entry and Exit
Study Notes
Amazon agrees e-book pricing deal with major publisher
21st October 2014
Why do businesses grow?
Study Notes
What is Market Concentration?
Study Notes
Patents
Study Notes
Competition and Markets Authority to investigate pie merger
20th December 2014
Oligopoly - What is Tacit Collusion?
Study Notes
Oligopoly - Collusion
Study Notes